Patent Application
20230122977
The subject matter disclosed herein is generally directed to regenerative approaches with tunable cell-cell and cell-matrix interactions to enhance the ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum, level of cell-cell and cell-matrix interaction.
Cartilage degeneration is particularly relevant in older populations, with 65% of those over 60 years old experiencing joint pain, causing a long-term disability and lower quality of life. In addition, immobile lifestyles caused by cartilage loss may cause up to a 24% increase in the likelihood of developing chronic heart disease, which is a leading cause of death. The complex physical and biochemical properties of articular cartilage have resulted in limited experimental and clinical success in replicating its structure and function, with few treatment options for those with cartilage loss.
Autologous Chondrocyte Implantation (ACI), a current treatment for cartilage injury, involves expanding chondrocytes in vitro, transplanting the expanded cells into a defect site, and holding them in place via a sutured periosteal flap. ACI studies show that the repaired tissue has similar biochemical properties to the native tissue and has better long-term outcomes than microfractures and other traditional methods. However, the procedure is dual staged, and there is often poor cell retention and dedifferentiation following implantation. Periosteal hypertrophy, ablation, leakage of chondrocytes, and nonhomogeneous cell distribution often occur after implantation, resulting in additional surgical requirements. These limitations reduce the potential of ACI as a treatment method. Additionally, during chondrocyte harvesting, inherent donor site morbidity may cause further cartilage loss. Thus, alternative methods have been explored for the repair of cartilage defect.
Currently, human cells are commercially expanded on cell culture bioreactors with synthetic microcarriers that do not mimic natural tissue. As these microcarriers are not natural to the expanded cells, the cells are detached and separated from the microcarriers, reseeded in a porous scaffold, and cultured in a bioreactor prior to implantation. The detachment of the cells from microcarriers and reseeding the cells in a scaffold negatively affects cell viability and functionality. Accordingly, there is a need to simplify the aforementioned process of cell expansion, separation, scaffold reseeding, and cultivation in bioreactors in order to increase cell viability and functionality, reduce contamination and cost, and enhance quality of the tissue regeneration implant.
Citation or identification of any document in this application is not an admission that such a document is available as prior art to the present disclosure.
The above objectives are accomplished according to the present disclosure by providing a method for forming a novel monolayer implant construct. The method may include forming at least one nanogel in at least one microcapsule via chain extending at least one first polyethylene oxide macromer with at least one lactide-glycolide, terminating at least one chain end with an acrylate functional group, crosslinking the at least one first polyethylene oxide macromer with at least one lactide-glycolide terminated on at least one chain end with an acrylate functional group with a second polyethylene oxide macromer with at least one lactide-glycolide terminated on at least one chain end with an acrylate functional group to form at least one nanogel, and conjugating at least one morphogen to the at least one nanogel to form at least one morphogen-encapsulated nanogel, forming at least one cartilage microparticle from articular cartilage, transferring the at least one cartilage microparticle to a cell culture bioreactor containing at least one cell culture medium wherein at least one cell adheres to the at least one cartilage microparticle, forming a suspension comprising the at least one cartilage microparticle with at least one cell adhered, the at least one morphogen-encapsulated nanogel, and at least one crosslinking agent in a tissue culture medium, and employing a cross-linking initiator to form a cross-linked monolayer implant. Further release of the at least one morphogen may be controlled via changing a composition of the nanogel to change a release duration of the at least one morphogen. Still, the articular cartilage may be harvested from frozen human cadaver or animal tissue. Yet further, the at least one cartilage microparticle is decellularized. Again, the at least one cartilage microparticle may range in size from 50 to 500 µm. Yet still, the at least one cell culture medium comprises at least one mesenchymal stem cell. Moreover, the suspension may be injected at a tissue injury site prior to employing the cross linking initiator.
In a further embodiment, a method for forming an implantable microgel-cell construct for a zonally structured tissue is provided. The method may include forming at least one nanogel in at least one microcapsule via chain extending at least one first polyethylene oxide macromer with at least one lactide-glycolide, terminating at least one chain end with an acrylate functional group, crosslinking the at least one first polyethylene oxide macromer with at least one lactide-glycolide terminated on at least one chain end with an acrylate functional group with a second polyethylene oxide macromer with at least one lactide-glycolide terminated on at least one chain end with an acrylate functional group to form at least one nanogel and conjugating at least one morphogen to the nanogel to form at least one morphogen-encapsulated nanogel, forming at least one microparticle, transferring the at least one microparticle to a cell culture bioreactor containing at least one cell culture medium wherein at least one cell adheres to the at least one microparticle, forming a first suspension comprising the at least one microparticle with at least one cell adhered and the at least one morphogen-encapsulated nanogel, allowing the first suspension to settle gravitationally on a surface and fuse via secretion of an extracellular matrix tor form a first monolayer, forming a second suspension comprising the at least one microparticle with at least one cell adhered and the at least one morphogen-encapsulated nanogel, and allowing the second suspension to settle gravitationally on a surface and fuse via secretion of an extracellular matrix or form a second monolayer atop the first monolayer to form a multilayer construct. Further, the first monolayer may range from 100 to 500 µm in thickness. Yet again, the first monolayer and the second monolayer may be formed with different extracelluar matrix compositions and/or different morphogen nanogels. Furthermore, the multilayer construct may comprise three or more monolayers. Still further, the at least three or more monolayers may be formed with different extracelluar matrix compositions and/or different morphogen nanogels. Yet still, the suspension may be transferred to a mold with a predefined shape. Further again, release of the at least one morphogen may be controlled via changing a composition of the nanogel to change a release duration of the at least one morphogen. Again further, the at least one microparticle may be decellularized. Further still, the at least one microparticle may range in size from 50 to 500 µm. Moreover, the at least one cell culture medium may comprise at least one mesenchymal stem cell.
In a still further embodiment, a novel multilayer cellular construct is provided. The multilayer cellular construct may include at least one decellularized cell-seeded fused microcarrier, wherein each layer of the at least one multilayer cellular construct mimics biochemical and cellular properties of at least one zone of a zonally structured tissue. Further, the decellularized cell-seeded fused microcarrier may include at least one cartilage microparticle. Still yet, the at least one cartilage microparticle may comprise either human or animal articular cartilage. Still further, the at least one cartilage microcarrier may ranges in size from 50 to 500 µm. Moreover, the at least one multilayer cellular construct maybe used to regenerate heart, skin, articular cartilage, blood vessel, nerve conduit, ligament and/or tendon tissue.
These and other aspects, objects, features, and advantages of the example embodiments will become apparent to those having ordinary skill in the art upon consideration of the following detailed description of example embodiments.
An understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure may be utilized, and the accompanying drawings of which:
The figures herein are for illustrative purposes only and are not necessarily drawn to scale.
Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
Unless specifically stated, terms and phrases used in this document, and variations thereof, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. Likewise, a group of items linked with the conjunction “and” should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as “and/or” unless expressly stated otherwise. Similarly, a group of items linked with the conjunction “or” should not be read as requiring mutual exclusivity among that group, but rather should also be read as “and/or” unless expressly stated otherwise.
Furthermore, although items, elements or components of the disclosure may be described or claimed in the singular, the plural is contemplated to be within the scope thereof unless limitation to the singular is explicitly stated. The presence of broadening words and phrases such as “one or more,” “at least,” “but not limited to” or other like phrases in some instances shall not be read to mean that the narrower case is intended or required in instances where such broadening phrases may be absent.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
All publications and patents cited in this specification are cited to disclose and describe the methods and/or materials in connection with which the publications are cited. All such publications and patents are herein incorporated by references as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and/or materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant application should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
Where a range is expressed, a further embodiment includes from the one particular value and/or to the other particular value. The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure. For example, where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g. the phrase “x to y” includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’. The range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘less than x’, less than y’, and ‘less than z’. Likewise, the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of greater than x’, greater than y’, and ‘greater than z’. In addition, the phrase “about ‘x’ to ‘y’”, where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’”.
It should be noted that ratios, concentrations, amounts, and other numerical data can be expressed herein in a range format. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. For example, if the value “about 10” is disclosed, then “10” is also disclosed.
It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible sub-ranges) within the indicated range.
As used herein, the singular forms “a”, “an”, and “the” include both singular and plural referents unless the context clearly dictates otherwise.
As used herein, “about,” “approximately,” “substantially,” and the like, when used in connection with a measurable variable such as a parameter, an amount, a temporal duration, and the like, are meant to encompass variations of and from the specified value including those within experimental error (which can be determined by e.g. given data set, art accepted standard, and/or with e.g. a given confidence interval (e.g. 90%, 95%, or more confidence interval from the mean), such as variations of +/-10% or less, +/-5% or less, +/-1% or less, and +/-0.1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosure. As used herein, the terms “about,” “approximate,” “at or about,” and “substantially” can mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art such that equivalent results or effects are obtained. In some circumstances, the value that provides equivalent results or effects cannot be reasonably determined. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about,” “approximate,” or “at or about” whether or not expressly stated to be such. It is understood that where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
As used herein, “control” can refer to an alternative subject or sample used in an experiment for comparison purpose and included to minimize or distinguish the effect of variables other than an independent variable.
The term “optional” or “optionally” means that the subsequent described event, circumstance or substituent may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed by the term “subject”.
As used herein, “substantially pure” can mean an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises about 50 percent of all species present. Generally, a substantially pure composition will comprise more than about 80 percent of all species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single species.
As used interchangeably herein, the terms “sufficient” and “effective,” can refer to an amount (e.g. mass, volume, dosage, concentration, and/or time period) needed to achieve one or more desired and/or stated result(s). For example, a therapeutically effective amount refers to an amount needed to achieve one or more therapeutic effects.
As used herein, “therapeutic” can refer to treating, healing, and/or ameliorating a disease, disorder, condition, or side effect, or to decreasing in the rate of advancement of a disease, disorder, condition, or side effect. A “therapeutically effective amount” can therefore refer to an amount of a compound that can yield a therapeutic effect.
As used herein, the terms “treating” and “treatment” can refer generally to obtaining a desired pharmacological and/or physiological effect. The effect can be, but does not necessarily have to be, prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof, such as cancer and/or indirect radiation damage. The effect can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease, disorder, or condition. The term “treatment” as used herein covers any treatment of cancer and/or indirect radiation damage, in a subject, particularly a human and/or companion animal, and can include any one or more of the following: (a) preventing the disease or damage from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and/or its symptoms or conditions. The term “treatment” as used herein can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (subjects in need thereof) can include those already with the disorder and/or those in which the disorder is to be prevented. As used herein, the term “treating”, can include inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
As used herein, the terms “weight percent,” “wt%,” and “wt. %,” which can be used interchangeably, indicate the percent by weight of a given component based on the total weight of a composition of which it is a component, unless otherwise specified. That is, unless otherwise specified, all wt% values are based on the total weight of the composition. It should be understood that the sum of wt% values for all components in a disclosed composition or formulation are equal to 100. Alternatively, if the wt% value is based on the total weight of a subset of components in a composition, it should be understood that the sum of wt% values the specified components in the disclosed composition or formulation are equal to 100.
As used herein, “water-soluble”, generally means at least about 10 g of a substance is soluble in 1 L of water, i.e., at neutral pH, at 25° C.
Various embodiments are described hereinafter. It should be noted that the specific embodiments are not intended as an exhaustive description or as a limitation to the broader aspects discussed herein. One aspect described in conjunction with a particular embodiment is not necessarily limited to that embodiment and can be practiced with any other embodiment(s). Reference throughout this specification to “one embodiment”, “an embodiment,” “an example embodiment,” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” or “an example embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the disclosure. For example, in the appended claims, any of the claimed embodiments can be used in any combination.
All patents, patent applications, published applications, and publications, databases, websites and other published materials cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.
In tissue engineering, progenitor cells are harvested from the patient, and expanded in three-dimensional microcarrier-based cell culture bioreactors. Next, the expanded cells are separated from the substrate, purified, and seeded in scaffolds, cultured in perfusion bioreactors to guide differentiation and maturation to the desired lineage and phenotype. Currently, human cells are commercially expanded on tissue culture bioreactors with synthetic microcarriers like polystyrene, dextran, or gelatin microbeads. These microcarrier-based substrates are synthetic and general in nature, meaning that the substrate does not mimic that of the natural tissue. As these microcarriers are not natural to the expanded cells, the cells are detached and separated from the microcarriers, reseeded in a porous scaffold, and cultured in a bioreactor prior to implantation. The detachment of the cells from microcarriers and reseeding the cells in a scaffold negatively affects cell viability and functionality.
All tissue engineered articular cartilage therapies fall into one of the following categories: (a) injectable cellular hydrogels, (b) implantable cell pellet, and (c) implantable cellular scaffolds. In injectable hydrogels, the progenitor cells are encapsulated within a natural/synthetic hydrogel matrix with high cell-matrix interaction but little to no cell-cell interaction. As there is extensive cell-cell contact in the superficial layer and deep layer, the injectable hydrogel fails to regenerate the superficial and deep zones of articular cartilage. In the cell pellet, there is extensive (almost 100%) contact between the cells in the pellet but there is complete lack of cell-matrix contact, which is beneficial to regeneration of the superficial zone. As there is extensive cell-matrix interaction and high compressive stiffness in the middle zone, the cell pellet fails to regenerate the compressively-loaded middle zone of articular cartilage. The implantable cellular scaffolds suffer from in homogenous cell seeding, insufficient cell to cell interaction, and incoordination between scaffold degradation and matrix formation. Therefore, regenerative approaches with tunable cell-cell and cell-matrix interactions could enhance our ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum levels of cell-cell and cell-matrix interaction.
Articular cartilage serves as a good example of a multilayer, zonally structured tissue. The organization of articular cartilage is initiated from the early stages of embryonic development by condensation and lineage commitment of mesenchymal stem cells (MSCs) in the lateral plate mesoderm by up-regulation of transforming growth factor-ß1 (TGFß1), the master regulator of chondrogenesis. Following condensation, MSCs begin differentiating into zone-specific chondrocytes via spatiotemporal expression of multiple morphogens. First, the condensed MSCs differentiate into pre-chondrocytes by up-regulation of bone morphogenetic protein-7 (BMP7) via the activation of Wnt/ß-catenin pathway via Smad 2/3/4 and transcription factors TCF/Lef1. The early structure of fetal articular cartilage is remarkably similar to that of the superficial zone of adult tissue. Next, the pre-chondrocytes in the developing fetal cartilage differentiate and adopt a pre-hypertrophic morphology driven by localized expression of insulin growth factor-1 (IGF1) to generate the superficial and middle zones. Next, the pre-hypertrophic chondrocytes differentiate to hypertrophic chondrocytes by localized expression of Indian hedgehog (IHH) through a pathway independent of parathyroid hormone-related protein (PTHrP). The spatiotemporal gradients in BMP7, IGF1, and IHH further divides the developing fetal cartilage into three distinct zones, namely the superficial, middle, and calcified zones. The maturation of stratified structure of articular cartilage is not limited to prenatal period as it continues during infancy, childhood, adolescence, and adulthood. Therefore, there is a need to develop multilayer cellular constructs with each layer having a zone-specific cellularity, extracellular matrix composition, and growth factor for regeneration of microstructured human tissues.
In this disclosure, a novel composition and process is developed to form multilayer cellular constructs, with each layer mimicking the biochemical and cellular properties of individual zones of articular cartilage, by sequential gravitational settling of cell-embedded, articular cartilage-based microcarriers. The process for production of a multilayer cellular construct using decellularized, cell-seeded, fused microcarriers, based on fetal or adult bovine articular cartilage tissue, is shown in
The process described above for articular cartilage regeneration serves as an example and this invention is not limited to articular cartilage. CMPs generated from any animal or cadaver tissue can be used to culture and expand cells for regeneration of the same tissue in a human patient. The composition and process used to generate the multilayer microgel-cell construct can be used for regeneration of any zonally structured tissue.
Tissue engineering aims to make cellular constructs for implantation in an injured tissue defect in a human patient to restore, maintain, repair, regenerate or improve the function of the injured tissue. The process of engineering a tissue include a) harvesting cells that are capable of being grown or stem cells from the patient, b) expanding the harvested cells in a cell culture bioreactor using microcarriers as a substrate, c) detaching and separating the cells from the microcarrier substrate, d) making a porous scaffold with a geometry similar to that of the tissue defect, e) seeding the expanded cells and growth factors homogeneously inside the porous scaffold, f) guiding maturation of the seeded cells to the lineage of the tissue that is being repaired using tissue culture bioreactors, g) and implanting the construct (scaffold+cells+growth factor) in the tissue defect regenerating the injured tissue.
Tissue engineered constructs fall into one of the following categories: (a) injectable cellular hydrogels, (b) implantable cell pellets, and (c) implantable cellular scaffolds. In injectable hydrogels, the progenitor cells are encapsulated within a natural/synthetic hydrogel matrix with high cell-matrix interaction but little to no cell-cell interaction. In the cell pellet, there is extensive (almost 100%) contact between the cells in the pellet but there is lack of cell-matrix contact. The implantable cellular scaffolds suffer from in homogenous cell seeding, insufficient cell-cell interaction, and lack of synchronized scaffold degradation and matrix formation. Therefore, regenerative approaches with tunable cell-cell and cell-matrix interactions could enhance our ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum level of cell-cell and cell-matrix interaction.
This disclosure describes a novel composition and process to form multilayer microgel-cell construct as constructs for implantation in a tissue defect using decellularized, micronized tissue particles as microcarriers for cell expansion as well as a scaffold for delivery to the site of injury. The decellularized, micronized tissue particles eliminate the undesired step of cell separation from microcarriers and reseeding the cells in a scaffold. Further, the decellularized, micronized tissue particles enable tuning and optimizing the extent of cell-cell and cell-matrix interactions. In addition, the decellularized, micronized tissue particles enable the production of multilayer microgel-cell constructs to mimic the zonal structure of regenerating tissue. The decellularized, micronized tissue particles can be used for regeneration of all human tissues from heart to skin, articular cartilage, blood vessels, nerve conduit, to ligament and tendon, among others.
Approximately 12% of all osteoarthritis cases are caused by PTOA. PTOA can occur in any age from any acute physical trauma such as sport, vehicle accident, fall, or military injury. PTOA results in some form of permanent disability in 28% of patients with traumatic skeletal injuries. The rapidly applied load in traumatic injuries focally disrupts the articular cartilage beginning with cell death, inadequate synthesis of proteoglycans, and disturbed proteoglycan to water ratio, which leads to decreased stiffness and accelerated damage to the remainder of the joint. PTOA is diagnosed on average 19 months following traumatic injury such that the focal articular disruption has advanced to a full-thickness defect.
Conventional clinical approaches to treat full-thickness chondral defects such as debridement, lavage, subchondral drilling, microfracture, and abrasion arthroplasty create mechanically-inferior fibrocartilage.
Osteochondral autograft transfer or mosaicplasty suffers from an additional surgical intervention and donor site morbidity. Autologous chondrocyte implantation (ACI) reduces fibrocartilage formation but it fails to restore zonal organization of the articular cartilage and in some cases leads to peripheral hypertrophy and calcification. For example, 33% of ACI procedures performed on patients suffering from PTOA of the knee resulted in permanent disability. Recently, injection or implantation of a cellular matrix with bulk properties mimicking those of the thickest zone of the native articular cartilage (middle and deep zones) to regenerate the injured tissue has been reported. However, regenerative approaches that do not take into consideration the zonal structure of articular cartilage lead to degeneration into inferior fibrocartilage after implantation, failure of the therapy and patient rehospitalization.
The articular cartilage is bounded in the thickness direction by the synovial fluid next to the superficial layer and by the bone tissue next to the calcified layer. As a result of proximity to the synovial fluid on one side and the bone tissue on the other side, articular cartilage has a stratified structure in which the chemical composition, cellularity, and mechanical stiffness varies continuously from the superficial layer to the calcified layer. The stratified structure of articular cartilage can be divided roughly into zones including the superficial zone (in direct contact with the synovial fluid), transition zone, middle zone, deep zone, and final the calcified zone. Each zone is defined by its unique chemical composition, cellularity, morphogens, and mechanical properties. The superficial zone is characterized by pre-chondrocytes with high expression of superficial zone protein (SZP) with low friction and joint lubrication as its functions. The transition, middle, and deep zones are characterized by prehypertrophic chondrocytes with high expression of glycosaminoglycans (GAG) and aggrecans (AGCs) with high water content to withstand the high compressive load exerted on the articular cartilage. The calcified zone is characterized by hypertrophic chondrocytes with high expression of collagen type X (Col X) and alkaline phosphatase (ALP) for the formation of a mineralized matrix for load transfer from the calcified zone to the underlying bone tissue. Therefore, injectable or implantable multilayer tissue constructs that simulate the zonal structure of articular cartilage would significantly improve the outcome and prevent permanent disability in patients suffering from PTOA.
Tissue-specific microcarriers for culture and expansion of cells, this approach could be used for culture and expansion of cells from all human tissues: articular cartilage microcarriers have been developed in Dr. Jabbari’s laboratory for culture and expansion of mesenchymal stem cells. Many potential uses exist for the current disclosure. -Cellular constructs for repair and regeneration of human tissues based on fused cell-seeded microcarriers with tissue-specific microcarriers and cells: Microgel-cell constructs have been developed in Dr. Jabbari’s laboratory for regeneration of articular cartilage tissue based on microcarriers from articular cartilage tissue and mesenchymal stem cells. -Multilayer cells constructs for simulating and mimicking the microstructure of human tissues: Multilayer microcell constructs have been developed in Dr. Jabbari’s laboratory for regeneration of zonal structure of articular cartilage with different layers simulating the superficial and calcified zone of articular cartilage. This approach can be used to simulate the microstructure of all human tissues from heart to skin, articular cartilage, blood vessels, nerve conduit, to ligament and tendon.
The objective of the current disclosure is to develop a 3D microcarrier-based cell culture system that recreates the zonal structure of articular cartilage and can be implanted directly in an articular cartilage defect. To achieve the objective, fetal or adult bovine articular cartilage was decellularized and ground to form cartilage microparticles (CMPs) as three-dimensional substrates for expansion and delivery of human mesenchymal stem cells (MSCs). MSCs were expanded on fetal or adult CMPs in suspension culture to form fCMP-MSCs or aCMP-MSCs, respectively. The MSCs cultured on fetal or adult CMPs retained the expression of MSC markers. The MSCs, without detachment from CMPs, were used to form injectable hydrogels or implantable cells sheets for delivery to the site of articular cartilage defect.
For the injectable hydrogel, adult or fetal CMP-MSCs were suspended in alginate hydrogel, injected in a mold, cross-linked with calcium chloride, and cultured in chondrogenic medium.
For the implantable cell sheet, CMP-MSCs were suspended in culture medium, injected in a mold, allowed to settle gravitationally on the mold’s bottom surface, and incubated in chondrogenic medium for 48 h to form a monolayer cell sheet.
The previous steps were repeated to form a bilayer cell sheet consisting of fetal CMP-MSCs on top of adult CMP-MSCs. The injectable or implantable CMP-MSCs constructs were characterized with respect to cellularity, expression of chondrogenic markers, and compressive modulus. The injectable CMP-MSCs hydrogels (fetal or adult) had significantly higher expression of chondrogenic markers and compressive modulus after four (4) weeks incubation in chondrogenic medium compared to MSCs directly encapsulated in alginate hydrogel; implantable CMP-MSCs cell sheets had significantly higher expression of chondrogenic markers and compressive modulus compared to MSCs in the pellet culture. The implantable approach is potentially useful for creating multilayer cellular constructs by sequential settling of suspended CMP-MSCs in the medium to mimic the stratified structure of articular cartilage.
A promising alternative to chondrocyte harvesting is the use of “adult human mesenchymal stem cells”, hereafter referred to as MSCs. Based on previous studies, bone marrow and synovium derived MSCs have the highest chondrogenic potential compared to other sources. See, M. Amemiya, K. Tsuji, H. Katagiri, K. Miyatake, Y. Nakagawa, I. Sekiya, T. Muneta, H. Koga, Synovial fluid-derived mesenchymal cells have non-inferior chondrogenic potential and can be utilized for regenerative therapy as substitute for synovium-derived cells,Biochem Biophys Res Commun 523(2) (2020) 465-472 and X.B. Peng, Y. Zhang, Y.Q. Wang, Q. He, Q. Yu, IGF-1 and BMP-7 synergistically stimulate articular cartilage repairing in the rabbit knees by improving chondrogenic differentiation of bone-marrow mesenchymal stem cells, J Cell Biochem 120(4) (2019) 5570-5582. Although MSCs delivered in a supportive scaffold promote the expression of chondrogenic markers and produce a cartilage-like matrix in vivo, the approach of encapsulating MSCs in a uniform matrix, without gradients, leads to fibrocartilage formation and tissue degeneration. See, A.R. Armiento, M. Alini, M.J. Stoddart, Articular fibrocartilage - Why does hyaline cartilage fail to repair?, Adv Drug Deliv Rev 146 (2019) 289-305 and Y. Qi, Y. Du, W. Li, X. Dai, T. Zhao, W. Yan, Cartilage repair using mesenchymal stem cell (MSC) sheet and MSCs-loaded bilayer PLGA scaffold in a rabbit model, Knee Surgery, Sports Traumatology, Arthroscopy 22(6) (2014) 1424-1433. The formation of inferior fibrocartilage tissue is rooted in the inability of cellular tissue constructs to recapitulate the stratified structure of articular cartilage, that is, to provide a lubricating surface for the gliding joint motion and a loading-bearing matrix for interface with the underlying bone. See, D.F. Amanatullah, S. Yamane, A.H. Reddi, Distinct patterns of gene expression in the superficial, middle and deep zones of bovine articular cartilage, J Tissue Eng Regen Med 8(7) (2014) 505-14.. There is clearly a need for novel engineering approaches to recreate the zonal structure of full-thickness articular cartilage to inhibit the formation of fibrocartilage tissue.
The stratified structure of articular cartilage is composed of the superficial, middle, deep and calcified zones with each zone having a defined protein expression, cellularity, ECM composition and structure. See, S.P. Grogan, S.F. Duffy, C. Pauli, J.A. Koziol, A.I. Su, D.D. D’Lima, M.K. Lotz, Zone-specific gene expression patterns in articular cartilage, Arthritis Rheum 65(2) (2013) 418-28.
The superficial zone is populated with pre-chondrocytes expressing superficial zone protein (SZP) for joint lubrication and collagen types IX/II forming thin collagen fibrils. The middle/deep zones are characterized by pre-hypertrophic chondrocytes expressing aggrecan (AGC) and glycosaminoglycan (GAG) for compressive strength and collagen type II forming collagen fibrils thicker than those in the superficial zone. The calcified zone is populated with hypertrophic chondrocytes expressing alkaline phosphatase (ALP) and collagen type X, forming a mineralized matrix to interface with the subchondral bone.
It is well established that fetal articular cartilage, with a stratified structure from week 12 of gestation, has a higher regenerative capacity compared to the adult. See L. Wu, C. Bluguermann, L. Kyupelyan, B. Latour, S. Gonzalez, S. Shah, Z. Galic, S. Ge, Y. Zhu, F.A. Petrigliano, A. Nsair, S.G. Miriuka, X. Li, K.M. Lyons, G.M. Crooks, D.R. McAllister, B. Van Handel, J.S. Adams, D. Evseenko, Human developmental chondrogenesis as a basis for engineering chondrocytes from pluripotent stem cells, Stem Cell Reports 1(6) (2013) 575-89. This higher regenerative capacity is attributed to differences in cellularity and ECM composition between fetal and adult articular cartilage. The average cell density of fetal articular cartilage is 250 M cells/mL compared to 30 M cells/mL for the adult. The fraction of Col II in fetal articular cartilage is 77% of total collagen compared to 86% for the adult; the fraction of Col IX in fetal is 10% compared to 1% for the adult. The fetal articular cartilage has higher fraction of Col X compared to the fetal. See, A.G. Nerlich, T. Kirsch, I. Wiest, P. Betz, K. von der Mark, Localization of collagen X in human fetal and juvenile articular cartilage and bone, Histochemistry 98(5) (1992) 275-81.. Engineering approaches that mimic cellularity, ECM composition and structure of fetal articular cartilage could potentially accelerate regeneration of full-thickness articular cartilage defects.
We previously demonstrated for the first time that high cellularity, low matrix stiffness and combination of TGF-ß1 and BMP-7 led to chondrogenic differentiation of MSCs to the superficial zone phenotype of articular cartilage; medium cellularity and stiffness, and combination of TGF-ß1 and IGF-1 led to the middle zone phenotype; and low cellularity, high matrix stiffness and combination of TGF-ß1 and hydroxyapatite (HA) led to the calcified zone phenotype. See, T. Karimi, D. Barati, O. Karaman, S. Moeinzadeh, E. Jabbari, A developmentally inspired combined mechanical and biochemical signaling approach on zonal lineage commitment of mesenchymal stem cells in articular cartilage regeneration, Integrative Biology 7(1) (2014) 112-127 and S. Moeinzadeh, S.R.P. Shariati, E. Jabbari, Comparative effect of physicomechanical and biomolecular cues on zone-specific chondrogenic differentiation of mesenchymal stem cells, Biomaterials 92 (2016) 57-70. Further, we recently demonstrated that MSCs encapsulated in digested, decellularized articular cartilage can be sequentially differentiated to the superficial zone phenotype, followed by the middle and calcified zones of articular cartilage chondrocytes by sequential, timed supplementation with chondrogenic medium with BMP-7, IGF-1 and Indian hedgehog (IHH). S. Moeinzadeh, M. Monavarian, S. Kader, E. Jabbari, Sequential zonal chondrogenic differentiation of mesenchymal stem cells in cartilage matrices, Tissue Engineering Part A 25(3-4) (2019) 234-247. Although decellularized articular cartilage has been used as a matrix to stimulate chondrogenic differentiation of progenitor cells, see W.J. Vas, M. Shah, T.S. Blacker, M.R. Duchen, P. Sibbons, S.J. Roberts, Decellularized Cartilage Directs Chondrogenic Differentiation: Creation of a Fracture Callus Mimetic, Tissue Engineering Part A 24(17-18) (2018) 1364-1376, we showed for the first time that MSCs encapsulated in digested, decellularized, fetal bovine articular cartilage differentiated to the superficial zone phenotype of chondrocytes in chondrogenic medium whereas in the adult the MSCs differentiated to the calcified phenotype.
Owing to their large surface area, microcarriers like polystyrene or dextran microbeads are used in bioreactors for the expansion of MSCs. See C. Loubiere, C. Sion, N. De Isla, L. Reppel, E. Guedon, I. Chevalot, E. Olmos, Impact of the type of microcarrier and agitation modes on the expansion performances of mesenchymal stem cells derived from umbilical cord, Biotechnol Prog 35(6) (2019) e2887 and A.M. de Soure, A. Fernandes-Platzgummer, C.L. da Silva, J.M. Cabral, Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells, J Biotechnol 236 (2016) 88-109. Biodegradable microcarriers, based on poly(2-oxazoline) or alginate, have been developed as a 3D matrix for cultivation of stem cells and delivery to the site of regeneration. See S. Lück, R. Schubel, J. Rüb, D. Hahn, E. Mathieu, H. Zimmermann, D. Scharnweber, C. Werner, S. Pautot, R. Jordan, Tailored and biodegradable poly (2-oxazoline) microbeads as 3D matrices for stem cell culture in regenerative therapies, Biomaterials 79 (2016) 1-14 and S.I. Somo, K. Langert, C.-Y. Yang, M.K. Vaicik, V. Ibarra, A.A. Appel, B. Akar, M.-H. Cheng, E.M. Brey, Synthesis and evaluation of dual crosslinked alginate microbeads, Acta biomaterialia 65 (2018) 53-65. Commonly used microcarriers may cause undesirable phenotypic changes in MSCs. Further, an additional step is required to detach and separate the cells from the carrier for clinical applications.
The current disclosure provides a developmentally inspired, biomimetic microcarrier, based on decellularized articular cartilage, hereafter referred to as cartilage microparticles (CMPs), that will enhance the regenerative capacity of MSCs for articular cartilage defects. The MSCs adhered to CMPs, hereafter referred to as CMP-MSCs, can potentially mimic the process of fetal development of articular cartilage, in combination with zone-specific growth factors, following injection in the joint capsule using minimally invasive arthroscopic techniques. See, T.H. Yoon, M. Jung, C.H. Choi, H.S. Kim, Y.H. Lee, Y.S. Choi, S.J. Kim, S.H. Kim, Arthroscopic gel-type autologous chondrocyte implantation presents histologic evidence of regenerating hyaline-like cartilage in the knee with articular cartilage defect, Knee Surg Sports Traumatol Arthrosc 28(3) (2020) 941-951. Further, CMP-MSCs can be used to assemble multilayer constructs with gradients in cell density, matrix composition, and morphogens to stimulate regeneration of zonal structure of articular cartilage.
The following approach was used to test the hypothesis that CMP-MCs enhance chondrogenesis for articular cartilage regeneration, as illustrated schematically in
Paraformaldehyde, formalin, paraffin, ethylenediaminetetraacetic acid (EDTA), penicillin G, streptomycin and tris(hydroxymethyl)aminomethane (Tris) were received from Sigma-Aldrich (St. Louis, MO). The sodium salt of pyruvic acid, L-proline, DNase I and RNase A were received from Amresco (Dublin, Ireland). Sodium alginate was received from Ward’s Science (Henrietta, NY). Iodoacetic acid and calcium chloride were received from ThermoFisher Scientific (Rockford, IL). Dichloromethane (DCM, Acros Organics, Pittsburg, PA) was dried by distillation over calcium hydride. Diethyl ether, dimethylformamide (DMF) and hexane were received from VWR (Bristol, CT) and used as received. Polyester filter sieves with 80, 90, 180, 190, 240 and 250 µm pore size were obtained from Rosin Tech (Los Angeles, CA). Nylon cell strainers with 40 and 70 µm sizes were received from Corning (Canton, NY). Polystyrene microparticles with 50 µm diameter and no surface modification were received from Advance Scientific (Moffat Beach, QLD, Australia).
Full-thickness adult and fetal articular cartilage harvested from the bovine femoral condyles were received from Animal Technologies (Tyler, TX). Adult human mesenchymal stem cells, hereafter referred to as MSCs, harvested from healthy human bone marrow with high expression of CD105, CD166, CD29, and CD44 and low expression of CD14, CD34 and CD45 markers and TGF-ß1 were received from Lonza (Allendale, NJ). Dulbecco’s modified eagle medium (DMEM) cell culture medium, Dulbecco’s phosphate-buffer saline (PBS), fetal bovine serum (FBS), trypsin-EDTA, Quant-it PicoGreen dsDNA reagent kit, and the live/dead staining kit, consisting of acetomethoxy derivative of calcein (cAM) and ethidium homodimer (EthD) were received from Life Technologies (Grand Island, NY). QuantiChrom alkaline phosphatase (ALP) assay kit was received from Bioassay Systems (Hayward, CA). 1,9-dimethylmethylene blue (DMMB) assay kit for quantification of glycosaminoglycan (GAG) content, hematoxylin and eosin-Y (H&E) for staining cell nuclei and cytoplasm, and Alcian blue for GAG staining were received from Sigma-Aldrich. PicoGreen assay kit for quantification of double-stranded DNA content was received from Molecular Probes (ThermoFisher Scientific, Waltham, MA). All primary and secondary antibodies were received from Santa Cruz Biotechnology (Dallas, TX). All forward and reverse primers were synthesized and received from Integrated DNA Technologies (Coralville, IA).
Full thickness articular cartilage samples, harvested from fetal or adult bovine femoral condyles, were decellularized as we described previously. Briefly, the articular cartilage samples were dissected with a scalpel into 5 × 5 × 2 mm pieces, the dissected pieces were frozen in liquid nitrogen and milled. The milled fragments were decellularized by immersion in 10 Mm Tris/1% triton solution for 24 h followed by sonication for 2 h at 55 kHz. Next, the sonicated fragments were immersed in nuclease solution consisting of 1 U/mL deoxyribonuclease and 1 U/mL ribonuclease in PBS for 72 h at 37° C. to degrade DNA and RNA. See T.W. Gilbert, T.L. Sellaro, S.F. Badylak, Decellularization of tissues and organs, Biomaterials 27(19) (2006) 3675-3683. The decellularized fragments were washed 3X in PBS, centrifuged, the supernatant was discarded, and the solid was freeze-dried.
The freeze-dried fragments were further grinded (Hamilton Beach, Southern Pines, NC) and sorted for size by progressively passing through sieves ranging in size from 80 to 300 µm. First, the soft fragments were passed through 80 and 300 µm sieves to eliminate sizes <80 µm and >300 µm. Next, the soft, fetal or adult decellularized cartilage microparticles, hereafter referred to as CMPs, were passed through a 90 µm sieve to collect a fraction with 40-110 µm size range, which is referred to as the 90 µm CMPs. Next, the >90 µm CMPs were passed through a 190 µm sieve to collect a fraction with 60-220 µm size range, which is referred to as the 190 µm CMPs. Then, the >190 µm CMPs were passed through a 250 µm sieves to collect a fraction with 60-300 µm size range, which is referred to as the 250 µm CMPs. The >250 µm fraction was further grinded and the above process was repeated to divide the particles into three fractions with average sizes of 90, 190 and 250 µm. Fetal and adult CMPs are hereafter referred to as fCMPs and aCMPs, respectively.
Microparticle size distribution: The sieved CMPs were imaged with a light microscope to determine their size distribution. The captured 2D images were analyzed with ImageJ software (National Institutes of Health, Bethesda, MD) to determine the average size as we described previously. See O. Karaman, A. Kumar, S. Moeinzadeh, X. He, T. Cui, E. Jabbari, Effect of surface modification of nanofibres with glutamic acid peptide on calcium phosphate nucleation and osteogenic differentiation of marrow stromal cells, J Tissue Eng Regen Med 10(2) (2016) E132-46. After size analysis, the three CMP size fractions, from fetal and adult bovine articular cartilages, were immersed in liquid nitrogen and cut with a surgical blade to expose a freshly cut surface for morphological analysis. Next, the CMPs were coated with gold using a Denton Desk II sputter coater (Moorestown, NJ) at 20 mA for 75 s. The CMPs were imaged for morphological analysis with a TESCAN VEGA3 SBU variable-pressure scanning electron microscope (SEM; Kohoutovice, Czech Republic) at an accelerating voltage of 8 keV.
Measurements of water content and mass loss: The equilibrium water content of dried, decellularized CMPs was measured by incubation in phosphate buffer saline (PBS) at 37° C. as we described previously. See, D. Barati, S. Kader, S.R. Pajoum Shariati, S. Moeinzadeh, R.H. Sawyer, E. Jabbari, Synthesis and Characterization of Photo-Cross-Linkable Keratin Hydrogels for Stem Cell Encapsulation, Biomacromolecules 18(2) (2017) 398-412. Briefly after swelling in PBS, the microparticles were filtered, unbound water was removed with a filter paper, and the sample weight was measured. After weighing, the sample was returned to a fresh solution and incubated until the next time point. This process was repeated until equilibrium or maximum swelling was achieved. The water content of CMPs at equilibrium was calculated as the difference between the initial and swollen weight divided by the total weight of the CMPs. The mass loss of CMPs samples was measured at one time point after 8 weeks of incubation in PBS. After 8 weeks, the CMPs were filtered, freeze-dried, and the sample weight was measured. Mass loss was defined as the difference between the initial and final weight of the dry CMPs divided by the initial dry weight.
MSCs (passage 3-5) were expanded in a high glucose DMEM medium supplemented with 10% FBS, 100 units/mL penicillin G, and 100 µg/mL streptomycin (basal medium, BM) as we previously described. See S. Moeinzadeh, M. Monavarian, S. Kader, E. Jabbari, Sequential zonal chondrogenic differentiation of mesenchymal stem cells in cartilage matrices, Tissue Engineering Part A 25(3-4) (2019) 234-247. CMPs were sterilized by immersion in ethanol for 2 h followed by exposure to ultraviolet (UV) radiation for 30 min. See Y.B. Kim, G.H. Kim, PCL/alginate composite scaffolds for hard tissue engineering: fabrication, characterization, and cellular activities, ACS combinatorial science 17(2) (2015) 87-99. The sterilized fCMPs or aCMPs were incubated in basal culture medium overnight to reach equilibrium swelling prior to cell seeding. The initial seeding density was calculated based on the typical average size of MSCs (18 µm average diameter, see L. Liu, L. Tseng, Q. Ye, Y.L. Wu, D.J. Bain, C. Ho, A New Method for Preparing Mesenchymal Stem Cells and Labeling with Ferumoxytol for Cell Tracking by MRI, Sci Rep 6 (2016) 26271.) and the size and surface area of CMPs. The initial cell seeding density was based on 1 × 106 MSCs occupying 20% of surface area of the CMPs (20% initial confluency). The volume porosity of CMPs was measured from the percent mass swellings assuming the CMP density did not change significantly with swelling. The CMPs were characterized by an average size equivalent to the diameter of a sphere and the CMP pores were assumed to be cubical in shape. The porosity, pore volume, surface area, and the number and mass of CMPs required for initial 1 × 106 MSC seeding to occupy 20% of the surface area for fCMPs and aCMPs with 90, 190 and 250 µm sizes are given in Table 1. For fCMPs or aCMPs with average sizes of 90, 190 and 250 µm, the amounts of microparticles required for 3 × 106 cells were 0.22, 0.48 and 0.64 mg, respectively. For 3D microcarrier cell culture, the specified amount of CMPs were added to the basal medium in ultra-low attachment T-75 tissue culture flasks followed by the addition of 3 × 106 MSCs. The flasks were securely mounted on a rocker mixer and placed in a humidified 5% CO2 incubator at 37° C. A doubling time of 48 h is reported for MSCs cultured on biological extracellular matrices (ECM). See P.J. Dolley-Sonneville, L.E. Romeo, Z.K. Melkoumian, Synthetic surface for expansion of human mesenchymal stem cells in xeno-free, chemically defined culture conditions, PLoS One 8(8) (2013) e70263. Based on this doubling time, fresh CMPs were added to the cell culture medium every 48 h to limit confluency to 40% and prevent cell crowding on the surface of CMPs. The analysis of live and dead images of the grown MSCs confirmed the absence of cell crowding on the surface and in the pore volume of the CMPs. MSCs cultured on 2D adherent culture flasks and MSCs cultured on 3D polystyrene microbeads (50 µm average size) were used as controls. At each time point (7, 14 and 21 days), the cultures were characterized with respect to cell number and viability, and mRNA expression of MSC markers.
Cell viability and growth: At each time point (7, 14 and 21 days), 2 mL of 0.05% trypsin/ 0.53 mM EDTA was added to 1 mL of the cell culture suspension and incubated for 15 min under shaking to detach MSCs from the CMPs. Next, the suspension was transferred on a 40 µm nylon cell strainer fixed on a 50 mL Falcon tube and washed with DMEM using an insulin syringe. The filtrate was centrifuged at 400 × g for 5 min as we described previously. See X. He, E. Jabbari, Material properties and cytocompatibility of injectable MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for marrow stromal cells, Biomacromolecules 8(3) (2007) 780-92, and the separated cells were counted with a hemocytometer. For cell viability, the CMPs were incubated with 1 µg/mL cAM/EthD to stain live and dead cells, respectively, as we described previously. See D. Barati, S. Kader, S.R. Pajoum Shariati, S. Moeinzadeh, R.H. Sawyer, E. Jabbari, Synthesis and Characterization of Photo-Cross-Linkable Keratin Hydrogels for Stem Cell Encapsulation, Biomacromolecules 18(2) (2017) 398-412. The stained cells were imaged using an inverted fluorescent microscope (Nikon Eclipse Ti-e, Nikon, Melville, NY).
Analysis of mRNA expression: The mRNA expression of CD105, CD166 and CD44 markers are up-regulated in MSCs whereas those of CD45 and CD34 are downregulated. See M.A. Crabbé, K. Gijbels, A. Visser, D. Craeye, S. Walbers, J. Pinxteren, R.J. Deans, W. Annaert, B.L. Vaes, Using miRNA-mRNA Interaction Analysis to Link Biologically Relevant miRNAs to Stem Cell Identity Testing for Next-Generation Culturing Development, Stem Cells Translational Medicine 5(6) (2016) 709-722. Therefore, MSCs cultured on CMPs were characterized phenotypically by their mRNA expression of CD105, CD166, CD44, CD45 and CD34 markers. Further, the CMP cultured MSCs were tested for differentiation to the chondrogenic lineage by measuring the mRNA expression of chondrogenic markers, SOX-9, Collagen I (Col I), Collagen II (Col II), and aggrecan (AGC), see S. Moeinzadeh, S.R.P. Shariati, E. Jabbari, Comparative effect of physicomechanical and biomolecular cues on zone-specific chondrogenic differentiation of mesenchymal stem cells, Biomaterials 92 (2016) 57-70 and S. Moeinzadeh, M. Monavarian, S. Kader, E. Jabbari, Sequential zonal chondrogenic differentiation of mesenchymal stem cells in cartilage matrices, Tissue Engineering Part A 25(3-4) (2019) 234-247. At each time point, MSCs were separated from the CMPs as described above and the total RNA of the homogenized cell suspension was isolated using TRIzol as we described previously. See, O. Karaman, A. Kumar, S. Moeinzadeh, X. He, T. Cui, E. Jabbari, Effect of surface modification of nanofibres with glutamic acid peptide on calcium phosphate nucleation and osteogenic differentiation of marrow stromal cells, J Tissue Eng Regen Med 10(2) (2016) E132-46. The genomic DNA was removed using deoxyribonuclease I (Invitrogen) as previously described. See, T. Karimi, D. Barati, O. Karaman, S. Moeinzadeh, E. Jabbari, A developmentally inspired combined mechanical and biochemical signaling approach on zonal lineage commitment of mesenchymal stem cells in articular cartilage regeneration, Integrative Biology 7(1) (2014) 112-127. 250 ng of the extracted RNA, as measured using a Nanodrop spectrophotometer, was converted to cDNA using Promega reverse transcription system (Madison, WI). The cDNA was amplified with Eppendorf SYBR green RealMasterMix (Hamburg, Germany) using a Bio-Rad CXF96 real-time quantitative polymerase chain reaction system (rt-qPCR; Hercules, CA) and the appropriate gene-specific primers as descried. See, S. Moeinzadeh, S.R.P. Shariati, E. Jabbari, Comparative effect of physicomechanical and biomolecular cues on zone-specific chondrogenic differentiation of mesenchymal stem cells, Biomaterials 92 (2016) 57-70. The primer sequences, as listed in Table 1, see
CMP-MSCs were encapsulated in sodium alginate hydrogel cross-linked with calcium chloride (CaCl2) using the following procedure. See, K.Y. Lee, D.J. Mooney, Alginate: properties and biomedical applications, Prog Polym Sci 37(1) (2012) 106-126. The sodium alginate solution was prepared by adding 3 g sodium alginate to 100 mL PBS under stirring. The CaCl2 solution was prepared by adding 1 g CaCl2 to 100 mL PBS under stirring. The alginate and CaCl2 solutions were sterilized by filtration. A suspension of adult or fetal CMP-MSCs in culture medium with average CMP sizes of 90, 190, and 250 µm was prepared as described herein. The suspension was transferred to a sterilized 15 mL Falcon tube, centrifuged and the medium was removed. Next, the alginate solution was added to the CMP-MSCs and mixed with a pre-sterilized glass rod. Then, the surface of a pre-sterilized, disk-shaped, Teflon mold with effective diameter of 2 cm and height of 1.5 mm was sprayed with the 1% CaCl2 solution using an insulin syringe. Next, the suspension of CMP-MSCs in sodium alginate was transferred to the mold and CaCl2 solution was sprayed on the exposed surface to crosslink the suspension. The gelation time was determined visually by placing a drop of the alginate solution on a glass ruler, followed by spraying CaCl2 solution on the drop, tilting the ruler by 45 degrees, observing movement of the drop on the titled ruler, and recording the time when the drop stopped moving as the gelation time. The crosslinking time of the CMP-MSC encapsulated alginate hydrogels ranged from 1-4 min. After crosslinking, the molds were transferred to a petri dish and cultured in chondrogenic medium for up to 8 weeks. The final concentration of alginate in the hydrogels was 3% w/v. MSCs encapsulated directly in the alginate gel, without CMPs, at a density of 1 × 105 cells/mL were used as the control group. aCMP-MSCs and fCMP-MSCs encapsulated in alginate gels is hereafter referred to as aCMP-MSCs/alg and fCMP-MSCs/alg, respectively.
The following approach was used to generate MSC cell sheets for implantation in an articular cartilage defect, as opposed to injection and in situ gelation. This approach is similar to MSC pellet cultures, see S. Giovannini, J. Diaz-Romero, T. Aigner, P. Heini, P. Mainil-Varlet, D. Nesic, Micromass co-culture of human articular chondrocytes and human bone marrow mesenchymal stem cells to investigate stable neocartilage tissue formation in vitro, Eur Cell Mater 20(245) (2010) 59., but adapted to CMP-MSCs. MSCs were cultured in 3D on adult/fetal CMPs, with average sizes of 90, 190, and 250 µm, to approximately 50% confluency to form adult/fetal CMP-MSCs, as described herein. Next, a suspension of adult/fetal CMP-MSCs in culture medium was transferred to a sterile Teflon mold (1.55 mm depth and 2 cm in diameter), the mold was placed in a sterile petri dish, and the assembly was incubated in a humidified 5% CO2 incubator at 37° C. for 48 h. During incubation, gravitational settling of aCMP-MSCs or fCMP-MSCs on bottom surface of the mold and secretion of extracellular matrix (ECM) led to the formation of an aCMP-MSCs or fCMP-MSCs monolayer cell sheet, hereafter referred to as aCMP-MSCs/ml and fCMP-MSCs/ml cell sheet, respectively. The CMP-MSC loading in the culture medium was adjusted to form a 0.75 mm thick cell sheet. To mimic the zonal structure of articular cartilage, the following approach was used to produce bilayer cell sheets. After formation of aCMP-MSC/ml, a suspension of fCMP-MSCs was transferred to the aCMP-MSC/ml mold, and the assembly was incubated for another 48 h. During incubation, gravitational settling of fCMP-MSCs on aCMP-MSCs/ml on bottom surface of the mold and secretion of extracellular matrix (ECM) led to the formation a bilayer cell sheet composed of fCMP-MSCs/ml on top of an aCMP-MSCs/ml, hereafter referred to as faCMP-MSCs/bl cell sheet. The CMP-MSC loading in the culture medium was adjusted to form a 1.5 mm faCMP-MSCs/bl cell sheet. After cell sheet formation, the medium was replaced with chondrogenic medium and the cell sheets were cultured for up to 8 weeks. The chondrogenic medium consisted of DMEM (4.5 g/mL glucose, 50 µg/ mL L-proline, 50 µg/mL ascorbic acid, 0.1 mM sodium pyruvate, 1% v/v insulin-transferrin-selenium premix) supplemented with the 10 ng/mL TGF-ß1. MSC pellets formed directly by centrifugation from suspension were used as the control group. commonly used pellet cultures. H. Rogan, F. Ilagan, F. Yang, Comparing Single Cell Versus Pellet Encapsulation of Mesenchymal Stem Cells in Three-Dimensional Hydrogels for Cartilage Regeneration, Tissue Eng Part A 25(19-20) (2019) 1404-1412.
At each time point, adult or fetal CMP-MSCs/alg, CMP-MSCs/ml and CMP-MSCs/bl were assessed with respect to compressive modulus, cellularity, and the expression of chondrogenic markers Sox-9, Collagen II (Col II) and aggrecan (AGC), the superficial zone marker SZP and calcified zone markers collagen X (Col X) and alkaline phosphatase (ALP). Cell viability was assessed by imaging with live & dead cell assay. The mono/bi-layer sheets were incubated with acetyl methoxy derivative of calcein (cAM) and ethidium homodimer (EthD) as live & dead cell stains, respectively, as we described previously, and the stained samples were imaged using the Eclipse Ti-E inverted fluorescent microscope. The CMP-MSCs/alg gels were rinsed twice with PBS and fixed with 4% paraformaldehyde for 3 h. After fixation, cells were permeabilized using PBS containing 0.1% Triton X-100 for 5 min, rinsed, and incubated with Alexa 488 phalloidin (1:200 dilution) and DAPI (1:5000 dilution) to stain actin filaments of the cell cytoskeleton and cell nuclei, respectively, as previously described. See, K. Yang, J. Sun, D. Wei, L. Yuan, J. Yang, L. Guo, H. Fan, X. Zhang, Photo-crosslinked mono-component type II collagen hydrogel as a matrix to induce chondrogenic differentiation of bone marrow mesenchymal stem cells, Journal of Materials Chemistry B 5(44) (2017) 8707-8718. The stained hydrogels were imaged with the Nikon inverted fluorescent microscope. At each time point, the samples (CMP-MSCs/alg, CMP-MSCs/ml, or CMP-MSCs/bl) were homogenized and the mRNA expression of chondrogenic markers Sox-9, Col II, Col X, SZP, AGC and ALP were measured as described herein.
The aCMP-MSCs/ml, fCMP-MSCs/ml, or faCMP-MSCs/bl, after 21 days of culture, were analyzed histologically for the expression of GAG and mineralized deposits as previously described, see T. Karimi, D. Barati, O. Karaman, S. Moeinzadeh, E. Jabbari, A developmentally inspired combined mechanical and biochemical signaling approach on zonal lineage commitment of mesenchymal stem cells in articular cartilage regeneration, Integrative Biology 7(1) (2014) 112-127. Briefly, the samples were fixed in formalin, embedded in paraffin, and cryo-sectioned to a thickness of 10 µm. The sections were divided into three groups with the first group stained with H&E to ascertain morphology of the encapsulated cells, Alcian blue to image GAG accumulation, and Alizarin red to image mineral deposits. The stained sections were imaged with a Nikon Optiphot Epi-florescence microscope.
At each time point, adult or fetal CMP-MSCs/alg, CMP-MSCs/ml, or CMP-MSCs/bl were loaded on the Peltier plate of an AR 2000ex rheometer (TA Instruments, New Castle, DE, USA) and subjected to a uniaxial compressive strain as we previously described. See, S. Moeinzadeh, D. Barati, X. He, E. Jabbari, Gelation characteristics and osteogenic differentiation of stromal cells in inert hydrolytically degradable micellar polyethylene glycol hydrogels, Biomacromolecules 13(7) (2012) 2073-86. A strain sweep from 0.01% to 500% strain at 10 Hz was performed to find the yield strain. Similarly, a frequency sweep from 0.01 to 100 Hz at 0.2% strain was done to find the crossover frequency. A sinusoidal shear strain with a frequency above the crossover frequency and a strain amplitude below the yield strain was exerted on the sample and the storage (G‘) and loss moduli (G“) were recorded with time. The slope of the linear fit to the stress-strain curve for strains of <10% was taken as the compressive modulus of the gel sample.
All experiments were done in triplicate and quantitative data is expressed as means + standard deviation. Significant differences between groups were evaluated using a two-way ANOVA with replication test and two-tailed Student’s t-tests. A value of p > 0.05 was considered statistically significant.
The percent equilibrium water contents of the aCMPs with average particle size of 90 µm, 190 µm and 250 µm were 18.6±0.9%, 19.6±0.9% and 20.0±1.5%, respectively; the water content of aCMPs were 15.3±1.5%, 16.5±0.6% and 18.0±0.8%. The water content of fCMPs was not affected by their particle size whereas the water content of aCMPs increased slightly with increasing size. For all particle sizes, the water content of fCMPs was significantly higher than aCMPs. The mass loss of fCMPs with average particle size of 90 µm, 190 µm and 250 µm after 8 weeks incubation in PBS was 4.4±0.2%, 5.2±0.2% and 6.5±0.1%, respectively; the mass loss of aCMPs was 3.7±0.3%, 4.3±1.3% and 5.8±0.5%. The mass loss of fetal and adult CMPs significantly increased with increasing particle size. For a given particle size, the mass loss of aCMPs was slightly lower than fCMPs. The mass loss data indicated that the fetal and adult CMPs are stable for up to 8 weeks with negligible hydrolytic degradation in the absence of enzymes.
Two culture methods were tested for expansion of MSCs on CMPs. In the first method, all CMPs were dispersed in basal culture medium along with MSCs initially at time zero. In the second method, all MSCs were added to the culture medium initially at time zero but the CMPs were added gradually every two days starting at zero time. The second method was more efficient as the surface area for cell adhesion and growth was increased gradually without allowing the percent cell confluency to fall below 20%, which improved cell-cell communication between the adhered MSCs. The second method allowed continuous expansion of MSCs by addition of more CMPs to the culture medium with incubation time.
The live (green) and dead (red) fluorescent images of a randomly selected particle from the CMP samples as a function of incubation time are shown in
Based on previous studies, MSCs harvested from the human bone marrow express CD105 and CD44 markers whereas the expression of CD45 and CD34 markers is down regulated. See M.C. Kastrinaki, I. Andreakou, P. Charbord, H.A. Papadaki, Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile, Tissue Eng Part C Methods 14(4) (2008) 333-9 and A.Y. Lee, J. Lee, C.L. Kim, K.S. Lee, S.H. Lee, N.Y. Gu, J.M. Kim, B.C. Lee, O.J. Koo, J.Y. Song, S.H. Cha, Comparative studies on proliferation, molecular markers and differentiation potential of mesenchymal stem cells from various tissues (adipose, bone marrow, ear skin, abdominal skin, and lung) and maintenance of multipotency during serial passages in miniature pig, Res Vet Sci 100 (2015) 115-24. Further, the as-received MSCs had high expression of CD105, CD166, CD29, and CD44 and low expression of CD14, CD34 and CD45 markers. Therefore, the MSCs expanded on fetal/adult CMPs were evaluated with respect to retention of the expression of CD 105, CD166 an CD44 markers and the absence of CD45 and CD34 expression, see
The results in
An injectable method was developed for the delivery of CMP-MSCs to the regeneration site. In the injectable method, fetal or adult CMPs were dispersed in an alginate precursor solution, the suspension was injected in a mold, and cross-linked with CaCl2 as the chelating agent.
An implantable cell sheet method was also developed for the delivery of CMP-MSCs to the regeneration site. In this method, mono- or bilayer cell sheets were generated by sequential gravitational settling of aCMP-MSCs or fCMP-MSCs and incubation in MSC medium for 48 h. Next, the cell sheets were cultured in chondrogenic medium for up to 28 day to induce chondrogenesis and articular cartilage tissue formation. To demonstrate ECM secretion and fusion of CMP-MSCs with incubation in chondrogenic medium, at different time points, the cultured fCMP-MSCs, aCMP-MSCs, and faCMP-MSCs cell sheets were stained with blue, red and purple dyes, respectively, and imaged with a microscope. The blue, red and purple images in Exhibit A of
The graphs in Exhibit B of
The compressive modulus of adult and fetal CMP-MSCs/alg hydrogels was measured as a function of percent CMPs (based on alginate weight) with incubation time in chondrogenic medium and the results are shown in
The compressive modulus of mono- and bi-layer cell sheets was measured as a function of CMP size with incubation time in chondrogenic medium and the results are shown in
The viability of MSCs in CMP-MSCs/alg or CMP-MSCs cell sheets was imaged by cAM/EthD live/dead staining. The nonfluorescent Calcein AM is converted to green fluorescent calcein in live cells after hydrolysis by intracellular esterases. The weakly fluorescent EthD becomes intensely red fluorescent after binding to single-strand DNA of dead cells. Phalloidin/DAPI image the shape and position of viable cells within a matrix by staining the cytoskeleton’s actin fibers and the DNA in the cell nucleus, respectively. Exhibit A in
This work describes a novel process to produce mono- or multi-layer cell sheets from fetal or adult articular matrix for regeneration of articular cartilage defects. First, fetal or adult bovine articular cartilage was minced, decellularized, and freeze-dried. Next, the freeze-dried extracellular matrix (ECM) was grinded and sieved to produce microparticles (CMPs) with average sizes in the range of 90-250 µm. Then, human MSCs were seeded on CMPs and expanded in a bioreactor to generate CMP-MSCs. MSCs expanded on fetal or adult CMPs in basal medium maintained their mesenchymal marker expression. Next, two approaches were used to generate cellular constructs for injection or implantation in a full-thickness articular cartilage defect. In one approach, CMP-MSCs were suspended in sodium alginate, injected into a mold, cross-linked with calcium chloride, and incubated in chondrogenic medium to generate an injectable construct for articular cartilage regeneration. In another approach, CMP-MSCs were suspended in a culture medium, allowed to settle on a mold surface by gravitational force, and fused by incubation in chondrogenic medium to generate an implantable cell sheet for articular cartilage regeneration.
Multilayer cell sheets can be generated by sequential settling and fusion of zone-specific CMP-MSCs to simulate the stratified structure of articular cartilage. Fetal or adult CMP-MSCs in alginate hydrogels showed significantly higher expression of chondrogenic markers after four weeks and compressive modulus after eight weeks of incubation in chondrogenic medium compared to MSCs directly encapsulated in alginate gels; CMP-MSCs cell sheets showed significantly higher expression of chondrogenic markers after four weeks and compressive modulus after eight weeks of incubation in chondrogenic medium compared to MSCs in a pellet culture. The higher quality of the generated tissues for CMP-MSCs groups was attributed to superior allocation of cell-cell and cell-matrix interactions compared to MSCs encapsulated in alginate or the MSC pellet. The cell sheet approach can be used to produce multilayer constructs with individual layers mimicking composition and cellularity of distinct zones of articular cartilage.
Various modifications and variations of the described methods, pharmaceutical compositions, and kits of the disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the disclosure. Although the disclosure has been described in connection with specific embodiments, it will be understood that it is capable of further modifications and that the disclosure as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the disclosure that are obvious to those skilled in the art are intended to be within the scope of the disclosure. This application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure come within known customary practice within the art to which the disclosure pertains and may be applied to the essential features herein before set forth.
This disclosure was made with government support under R56 ARO63745 awarded by the National Institute of Health, 1500242 by the National Science Foundation, and 1403545 by the National Science Foundation. The government may have certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 63187996 | May 2021 | US |
